What is Study medication?
The medicines we’re testing in our trial are ones that are already approved by the FDA for different renal disease managment. These include ACEi/ARB’s,SGLT2 inhibitors like Dapaglifozin and Hydroxychloroquine (HCQ), Mycophenolate mofetil (MMF), and Oral prednisolone, and other medications, which have shown benefits in other renal (kidney) diseases or have immune-modulating effects, so, these medications can protect the kidneys, reduce protein loss in urine, and potentially slow down the progression of IgA nephropathy.
Have these medications been used by others before in studies?
We were going to use Dapaglifozin (SGLT2i), Hydroxychloroquine (HCQ), Mycophenolate Mofetil (MMF), and Oral Prednisolone, budesonide all of which are FDA-approved medications with established roles in managing renal diseases. Yes, to date, huge people have received at least one dose of the same medication, that mentioned above in clinical studies across various indications.
For an instance, Dapaglifozin, have been supported by a wealth of clinical trials such as the CREDENCE trial, demonstrating significant renal protective effects in patients with type 2 diabetes with chronic kidney disease. Telmisartan is often prescribed to manage high blood pressure and reduce proteinuria (protein in the urine), which are common symptoms of IgA nephropathy. Additionally, it may help protect the kidneys from further damage. Hydroxychloroquine, traditionally used in lupus, has shown renal benefits in lupus nephritis, as endorsed by the American College of Rheumatology guidelines. Mycophenolate Mofetil allivetaes the presistant proteinuria in IgA nephropathy was documented in the literature and supported by KDIGO guidelines. Similarly, Oral Prednisolone’s role in reducing renal inflammation is well as mitigates the proteinuria along with ACEi/ARB’s, in numerous clinical trials and clinical practice guidelines recommending its use in conditions like nephrotic syndrome.
Will I receive the same medication?
In this study, participants will receive Standard of Care and with the study medication , in addition to continuing their current standard of care therapy. So, based on that the participants will assigned to any one of study medication with standard of care or standard of care alone.
